US Bancorp’s Starling Oncology STLN Stock Holding History

US Bancorp’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$310	Sell	57 -39	-41%	-$164	﹤0.01%	4090
2026 Q1	$295	Buy	+96	New	+$294	﹤0.01%	4061

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

US Bancorp's STLN Position: Q2 2026 in Review

US Bancorp reduced its Starling Oncology (STLN) stake by 41% in Q2 2026, selling an estimated $164 and leaving 57 shares worth $310. The position accounts for ﹤0.01% of the portfolio, ranked #4090.

US Bancorp first reported a position in STLN in Q1 2026 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

US Bancorp held 57 shares of Starling Oncology worth $310 as of Q2 2026.
US Bancorp sold 39 Starling Oncology shares in Q2 2026, an estimated $164.
Starling Oncology made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #4090 holding.
US Bancorp first reported a position in Starling Oncology in Q1 2026 and has held it in 2 quarters since.
119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.